SGEN Seattle Genetics Inc.

63.68
-0.40  -1%
Previous Close 64.08
Open 64.00
Price To book 15.88
Market Cap 9107972733
Shares 143,027,210
Volume 908,269
Short Ratio 12.62
Av. Daily Volume 1,025,856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial to be initiated.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 1/2 data presented at ESMO 2017. Response rate 32%.
Tisotumab Vedotin
Cervical Cancer
Phase 2 pivotal trial to be initiated 2H 2017.
Enfortumab vedotin
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
Phase 3 data released June 26, 2017 - primary endpoint met.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due in 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
PDUFA date under Priority review for sBLA filing December 16, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. Cramer’s Exec Cut: CEO reveals his company’s plans to dis...
  2. Cancer Space Update: Lung & Breast Cancer Studies in Focus
  3. Seattle Genetics Inks Clinical Collaborations for Cancer Drug
  4. Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics
  5. Cramer Remix: It’s not about sex appeal, it’s about timin...
  6. Seattle Genetics CEO talks new cancer treatment pipeline,...
  7. Cramer Remix: It’s not about sex appeal, it’s about timing
  8. Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
  9. This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck
  10. Seattle Genetics Begins Phase II Study of Cancer Candidate
  11. Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer
  12. See what the IHS Markit Score report has to say about Seattle Genetics Inc.
  13. Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
  14. Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
  15. Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
  16. Cancer Space Last Week Update: Pipeline Expansion in Focus
  17. Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017
  18. Cramer's lightning round: Why my charitable trust sold it...
  19. Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

SEC Filings

  1. 8-K - Current report 171125067
  2. CT ORDER - Confidential treatment order 171091173
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171088622
  4. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171088608
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17997238
  6. 8-K - Current report 17986389
  7. SC 13D - General statement of acquisition of beneficial ownership
  8. 8-K - Current report 17928866
  9. 8-K - Current report 17923887
  10. 8-K - Current report 17917467